SCHEMBL30983512

SCHEMBL30983512

CNC(=O)COc1ccc(-c2nc3c(OC4(C)CC4)ncnc3n2Cc2ccccc2)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PIK3CD O00329 3/20 0.36
▸ PDK2 Q15119 1/20 0.35
▸ ACSS2 Q9NR19 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CNR1 P21554 4/20 0.34
▸ CNR2 P34972 3/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ NCOA3 Q9Y6Q9 1/20 0.34
▸ FBP1 P09467 1/20 0.33
▸ PRKAB2 O43741 1/20 0.33
▸ PRKAG1 P54619 1/20 0.33
▸ PRKAA2 P54646 1/20 0.33
▸ PRKAA1 Q13131 1/20 0.33
▸ PRKAG3 Q9UGI9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268760 0.93 FBP1 (0.39) KMT2ASMN1; SMN2PIK3CDPDK2ACSS2
SCHEMBL30983954 0.92 PLA2G2A (0.39) KMT2APIK3CDHTTCNR1CNR2
SCHEMBL30983449 0.91 ALDH1A1 (0.42) KMT2ASMN1; SMN2PIK3CDPDK2HTT
SCHEMBL30983924 0.91 PLA2G2A (0.38) KMT2APIK3CDCNR1CNR2
SCHEMBL30983502 0.89 NPC1 (0.38) KMT2ASMN1; SMN2PIK3CDPDK2ACSS2
SCHEMBL30984034 0.89 PIK3CD (0.37) KMT2APIK3CDCNR1CNR2MEN1
SCHEMBL31268824 0.89 PIK3CD (0.34) PIK3CDPDK2POLBPRKAB2PRKAG1
SCHEMBL31269346 0.89 PIK3CD (0.34) PIK3CDPDK2CNR1POLBPRKAB2
SCHEMBL31321937 0.88 PLA2G2A (0.40) PIK3CDPDK2
SCHEMBL31269423 0.88 PIK3CD (0.37) PIK3CDPDK2PRKAB2PRKAG1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB KMT2A 880/4885SMN1; SMN2 2586/4885PIK3CD 434/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB KMT2A 880/4885SMN1; SMN2 2586/4885PIK3CD 434/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB KMT2A 880/4885SMN1; SMN2 2586/4885PIK3CD 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback